Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the vesting and lapsing of conditional share awards granted in 2009 and 2010 under the GlaxoSmithKline Performance Share Plan and the 2009 Deferred Annual Bonus Plan.
Key Financial Metrics and Performance Data
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. However, it discloses specific performance targets and results used to determine executive compensation:
- Adjusted Free Cash Flow (2010-2012): The company achieved £17.6 billion against a target of £17.8 billion.
- Total Shareholder Return (TSR) Ranking (2009-2012): Ranked 8th out of 11 comparator pharmaceutical companies (below median).
- Total Shareholder Return (TSR) Ranking (2010-2012): Ranked 6th out of 11 comparator pharmaceutical companies (median position).
- Share Price at Vesting (March 1, 2013): Ordinary Shares at £14.55 and American Depositary Shares (ADS) at US$44.03.
Material Changes and Compensation Outcomes
Material changes relate to the status of executive equity awards based on the performance metrics noted above:
- 2009 Performance Share Plan: The 30% portion of awards subject to a four-year TSR performance period (ending Dec 31, 2012) lapsed in full due to the company ranking below the median.
- 2010 Performance Share Plan:
- Free Cash Flow Element: 40% of this element vested (representing 16% of the total award) as the company narrowly missed the target.
- TSR Element (3-year): 30% of this element vested (representing 9% of the total award) due to median ranking; the balance lapsed.
- TSR Element (4-year): The remaining 30% of the total award remains outstanding, pending measurement in Q1 2014.
- Overall Vesting: 25% of the total 2010 award vested, while the balance subject to the three-year period lapsed.
- 2010 Deferred Annual Bonus (Sir Andrew Witty): 30% of the Deferred Shares vested based on median TSR performance; the balance lapsed. Matching Shares vested at 30% (8,529 shares) with 19,900 shares lapsing.
- Senior Executive Awards: Awards for senior executives appointed as PDMRs were split between EPS and operational targets, with specific vesting and lapsing amounts detailed for individuals including Mr. R Connor, Mr. P Thomson, and Dr. P Vallance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general corporate risks. The primary contingency noted is the future vesting of the four-year TSR element of the 2010 Performance Share Plan, which will be measured in the first quarter of 2014 following the performance period ending December 31, 2013.
Key Facts for Investor Verification
- Verify the specific number of shares vested versus lapsed for Executive Directors (e.g., Sir Andrew Witty, Dr. M. Slaoui) as detailed in the tables.
- Confirm the impact of the "below median" TSR ranking (8th of 11) on the 2009 awards, which resulted in a 100% lapse for that portion.
- Note that the 2010 free cash flow target was missed by £0.2 billion, resulting in partial vesting (16% of total award) rather than full vesting.
- Track the outstanding 30% of the 2010 TSR awards, which remain contingent on performance through December 31, 2013.
- Confirm the exercise deadline for the nil-cost options granted under the Deferred Annual Bonus Plan, which is February 21, 2020.